Cladribine — Membership Pricing

Other medications in Neurological

• Clobazam
• Diazepam
• Diazepam Rectal
• Dimenhydrinate
• Dimethyl Fumarate
• Donepezil
• Edaravone
• Entacapone

What Cladribine is approved for (FDA label)

Cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults.

Source: Read the full FDA label on DailyMed. Label effective date: June 19, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Cladribine (FDA label)

WARNING: MALIGNANCIES and RISK OF TERATOGENICITY WARNING: MALIGNANCIES and RISK OF TERATOGENICITY See full prescribing information for complete boxed warning. Malignancies Cladribine may increase the risk of malignancy. Cladribine is contraindicated in patients with current malignancy; evaluate the benefits and risks on an individual basis for patients with prior or increased risk of malignancy. ( 5.1 ) Risk of Teratogenicity Cladribine is contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception because of the risk of fetal harm. ( 5.2 ) Malignancies Treatment with cladribine may increase the risk of malignancy. Cladribine is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of cladribine on an individual patient basis. Follow standard cancer screening guidelines in patients treated with cladribine [see Contraindications (4) and Warnings and Precautions (5.1) ] . Risk of Teratogenicity Cladribine is contraindicated for use in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with cladribine in females of reproductive potential.

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Cladribine (FDA label)

Cladribine is available as 10 mg tablets. The tablets are white, round, debossed with "X10" on one side and plain on the other side. Tablets: 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Cladribine (FDA label)

The following serious adverse reactions and potential risks are discussed, or discussed in greater detail, in other sections of the labeling: Malignancies [see Warnings and Precautions (5.1) ] Risk of Teratogenicity [see Warnings and Precautions (5.2) ] Lymphopenia [see Warnings and Precautions (5.3) ] Infections [see Warnings and Precautions (5.4) ] Hematologic Toxicity [see Warnings and Precautions (5.5) ] Graft-Versus-Host Disease With Blood Transfusion [see Warnings and Precautions (5.6) ] Liver Injury [see Warnings and Precautions (5.7) ] Hypersensitivity [see Warnings and Precautions (5.8) ] Cardiac Failure [see Warnings and Precautions (5.9) ] Most common adverse reactions (incidence > 20%) are upper respiratory tract infection, headache, and lymphopenia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hopewell at 1-888-922-2116, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Cladribine (FDA label)

Cladribine is contraindicated: in patients with current malignancy [see Warnings and Precautions (5.1) ]. in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception during cladribine dosing and for 6 months after the last dose in each treatment course for females and 14 weeks for males.

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Cladribine (FDA label)

Lymphopenia: Monitor lymphocyte counts before, during and after treatment. ( 5.3 ) Infections: Serious, including life-threatening and fatal infections, have occurred. Screen patients for active and latent infections; delay treatment until infection is fully resolved or controlled. Vaccination of patients seronegative to varicella zoster virus (VZV) is recommended prior to treatment. Vaccination of patients seropositive to VZV with zoster vaccine recombinant, adjuvanted, is recommended prior to or during treatment. Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter. Monitor for infections. ( 5.4 ) Hematologic toxicity: Monitor complete blood count before, during, and after treatment. ( 5.5 ) Graft-versus-host-disease with blood transfusion: Irradiation of cellular blood components is recommended. ( 5.6 ) Liver injury: Clinically significant liver injury has occurred. Obtain tests prior to treatment.

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Cladribine (FDA label)

Table 3 Drug Interactions with Cladribine 7.1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system [see Warnings and Precautions (5.4) ] . Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short- term therapy with corticosteroids can be administered.

Source: FDA prescribing information (DailyMed). Set ID: e0b363cb-db83-44d6-89d0-1f7176be7459. SPL document ID: 549c44bf-67d2-9e14-e063-6294a90a9097. Label effective date: June 19, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.